Company Overview
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Key Highlights
- Biotechnology · Healthcare
- Led by Jamie Bligh
- 4 employees
- Based in Naples, FL
Price History
Loading…
Data from Twelve Data. Prices may be delayed.
Analyst Coverage
View All Coverage →No analyst coverage available.
Economic Calendar
View more →- Nov 6
Initial Jobless Claims
7:30 AM ET
- Nov 6
GDP Growth Rate (QoQ)
7:30 AM ET
- Nov 6
Pending Home Sales (MoM)
9:00 AM ET
- Nov 6
Natural Gas Inventories
9:30 AM ET
Crypto Prices
View more →
Bitcoin (BTC)
75,720 +0.33%
Company Facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Naples, FL, US
- Incorporated
- Mar 28, 2022
- Website
- www.cdtequity.com
Latest SEC Filings
View All Filings →- 424B3Nov 4, 2026
